Table 3.
Results of univariate and multivariate analyses of the prognostic factors for overall survival in younger (≤ 50 years) patients with lung adenocarcinoma (n = 49)
| Variable | No. | (%) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| Five‐year survival (%) | P | Hazard ratio | 95% confidence interval | P | ||||
| Age, years | ||||||||
| ≤ 40 | 7 | (14) | 42.9 | |||||
| > 40 | 42 | (86) | 56.9 | 0.4053 | ||||
| Gender | ||||||||
| Male | 23 | (47) | 39.0 | |||||
| Female | 26 | (53) | 67.5 | 0.0777 | 0.410 | 0.146–1.157 | 0.0922 | |
| Smoking history | ||||||||
| Non‐smoker | 27 | (55) | 62.9 | |||||
| Ever smoker | 22 | (45) | 45.1 | 0.1379 | ||||
| Pathology | ||||||||
| With lepidic growth | 16 | (33) | 76.9 | |||||
| Without lepidic growth | 33 | (67) | 44.4 | 0.0315 | 1.965 | 0.495–7.813 | 0.3369 | |
| Stage | ||||||||
| I–III | 42 | (86) | 62.1 | |||||
| IV | 7 | (14) | 14.3 | 0.0003 | 4.975 | 1.534–16.129 | 0.0075 | |
| EML4‐ALK fusion | ||||||||
| Negative | 44 | (90) | 59.4 | |||||
| Positive | 5 | (10) | NR | 0.0037 | 2.215 | 0.514–9.537 | 0.2856 | |
| EGFR | ||||||||
| Wild type | 36 | (73) | 46.6 | |||||
| Mutation | 13 | (27) | 82.1 | 0.0625 | 2.058 | 0.405–0.417 | 0.3843 | |
| KRAS | ||||||||
| Wild type | 48 | (98) | 54.6 | |||||
| Mutation | 1 | (2) | NR | NE | ||||
NE, not evaluable; NR, not reached.